Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio   Mottolese Marcella   Fabi Alessandra  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

By Murthy Rashmi K.   Varma Ankur   Mishra Priyankana   Hess Kenneth R.   Young Elliana   Murray James L.   Koenig Kimberly H.   Moulder Stacy L.   Melhem-Bertrandt Amal   Giordano Sharon H.   Booser Daniel   Valero Vicente   Hortobagyi Gabriel N.   Esteva Francisco J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

Blackwell Publishing

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite